A fundamental shift is under way throughout the pharmaceutical industry – we can all agree on that. What used to take decades to change and years to measure now seems to happen at the speed of light. Every functional area […]
Read MoreOff-label prescribing has made a splash in the news in recent months. A September 2009 settlement of a lawsuit against pharmaceutical giant Pfizer is once again bringing attention to the practice of off-label prescribing and marketing of pharmaceuticals. The settlement […]
Read MoreIMS Health’s annual summary of the US drug market shows a higher-than-normal increase in 2009, at least compared to the two previous years, when the annual sales grew 1.8% (2008) and 3.8% (2007). But the 5.1% increase is only just […]
Read MoreModel N’s latest software offering focuses on pricing analytics In that vision of a purchasing decision at a remote pharmacy causing a order to be filled at a warehouse, an invoice being issued to an insurer, and a reimbursement zipping […]
Read MoreBy Jeffrey Jung and John Tamisiea, McDermott, Will & Emery In the span of just over 10 years, specialized investment funds which initially purchased interests in royalty streams from out-licensed pharmaceutical intellectual property assets have evolved to offer successively larger […]
Read MoreMany industry managers have had their foot on the gas pedal to accelerate their company’s adjustment to Pharma 2.0—the replacement of the monolithic blockbuster-drug era with one of targeted therapies and outsourced partnering. Now, says Ernst & Young (New York) […]
Read MoreWhat a difference the past three years have made. When IMS Health first segregated what it calls “pharmerging” markets—developing countries with fast-growing economies—in late 2006, it projected that seven countries would constitute 12% of the world market by 2011, and […]
Read MoreWith increasing frequency in Europe, and now starting to show up in the US, biopharma companies and payers are entering into agreements to provide some form of risk sharing or price protection as new drugs are adopted into formularies. The […]
Read MoreIn normal times and for most industries, accounting, auditing and tax issues tend to hum along in the background—a necessary but relatively quiet part of business management. But for the biopharma industry, and in these times of financial systems turmoil, […]
Read MoreApproximately ten years ago, a new niche market emerged within the pharmaceutical industry: end-of-life-cycle pharmaceuticals. This phenomenon has risen out of several market factors and continues to grow as a market vehicle for the specialty pharmaceutical firms that sell them. […]
Read More
